Published
February 18, 2025
Updated
July 30, 2026
The Robitussin settlement resolved claims that products containing dextromethorphan were misleadingly marketed as non-drowsy.
Current Status
The court granted final approval on July 25, 2025. After an appeal was withdrawn, the administrator began issuing approved-claim payments on September 5, 2025. The May 12, 2025 claim deadline has passed.StatusPayments issued
Claim DeadlineMay 12, 2025 (Passed)
Settlement Fund$4.5 million
Distribution BeganSeptember 5, 2025
What Was This Case About?
The lawsuits alleged that covered Robitussin products were deceptively marketed as non-drowsy even though they contained dextromethorphan, which plaintiffs alleged can cause drowsiness. Haleon denied the allegations and asserted defenses.Who Was Covered?
The class included United States purchasers of covered Robitussin products for personal or household use from February 16, 2016 through January 21, 2025.What Benefits Were Available?
The net fund was distributed pro rata per approved claim. Quantity limits depended on whether proof of purchase was supplied. The agreement also required changes to covered product labeling and marketing.Official Information
Review the latest information on the Non-Drowsy Robitussin Settlement website.
Settlement Fund
$4.5 million
Case Titles
Calchi v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC; Papalia v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Case Numbers
7:22-cv-01341-KMK; 7:22-cv-02630-KMK
Court
U.S. District Court for the Southern District of New York
Current Milestone
Payments began September 5, 2025
Official Website
Non-Drowsy Robitussin Settlement
For more class actions, recalls, and refunds, keep scrolling below.
